N |
21 |
276 |
— |
Preoperative characteristics |
|
|
|
Age, years |
30.5 (23-34.8; 19-56) |
49 (30.2-57.8; 19-71) |
<0.001 |
Male gender |
13 (61.9) |
152 (55.1) |
0.544 |
Body mass index, kg/m2
|
20.2 (19-23; 17.7-27.9) |
22.1 (19.5-25.5; 14.7-58.1) |
0.062 |
Hemoglobin, g/L |
84 (78-91; 71-103) |
137 (121-149; 59-196) |
<0.001 |
Hemoglobin <90 g/L |
16 (76.2) |
11 (4.0) |
<0.001 |
Platelet count, x109/L |
153 (84-257; 37-550) |
273 (221-357; 52-659) |
<0.001 |
Platelet count <150 x109/L |
11 (52.4) |
19 (6.9) |
<0.001 |
aPTT, seconds |
49.5 (43.8-66.2; 34.5-97.1) |
32 (29-34.5;
17.7-108.5) |
<0.001 |
INR |
1.2 (1.1-1.4; 0.9-1.7) |
1.0 (0.9-1.1; 0.8-2.5) |
<0.001 |
Creatinine, µmol/L |
58 (33-70; 19-94) |
59 (50-72.5; 24-142) |
0.237 |
FVC, L |
1.62 (1.36-2.18; 0.73-3.23) |
1.88 (1.43-2.37; 0.39-4.98) |
0.316 |
FEV1, L |
0.97 (0.62-1.36; 0.41-2.30) |
0.73 (0.55-0.92; 0.20-3.61) |
0.037 |
Renal replacement therapy |
1 (4.8) |
1 (0.4) |
0.100 |
Mechanical ventilation |
8 (38.1) |
0 |
— |
Diagnosis |
|
|
|
Cystic fibrosis |
19 (90.5) |
108 (39.1) |
<0.001 |
COPD/emphysema/bronchiectasis |
0 |
99 (35.9) |
— |
α1-antitrypsin deficiency |
1 (4.8) |
34 (12.3) |
0.300 |
Pulmonary fibrosis/ILD |
1 (4.8) |
27 (9.8) |
0.448 |
Lymphangioleiomyomatosis |
0 |
5 (1,8) |
— |
Pulmonary hypertension |
0 |
3 (1.1) |
— |
Preoperative VV-ECMO duration, d |
8 (6.5-16; 1-53) |
— |
— |
Intraoperative characteristics |
|
|
|
Bilateral lung transplant |
21 (100) |
268 (97.1) |
— |
Cardiopulmonary bypass |
6 (28.6) |
94 (34.1) |
0.608 |
ECMO |
15(71.4) |
15 (5.4) |
<0.001 |
Transfusion (24h) |
|
|
|
Red blood cells, units |
13.5 (8.2-41.8; 5-53) |
3 (1-3, 0-71) |
<0.001 |
Platelets, pools |
3.5 (1.2-8.5; 0-21) |
1 (0-2; 0-18) |
<0.001 |
Fresh frozen plasma, units |
6 (2.5-11; 0-37) |
2 (0-4; 0-32) |
<0.001 |
Cryoprecipitate, units |
8 (38.1) (median 3.5 units) |
45 (16.3)
(median 2 units) |
0.022 |